Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) announced the completion of a phase two clinical trial of cannabis oil capsules treating uncontrolled chronic pain in cancer and non-cancer patients.
As quoted in the press release:
Tetra Bio-Pharma, a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial of cannabis oil capsules. The trial evaluated the safety and efficacy of different doses and ratios of medical cannabis oil comprised of [tetrahydrocannabinol] THC and [cannabidiol] CBD, for the treatment of uncontrolled chronic pain in cancer and non-cancer patients.
The Phase 2 trial was conducted by Montreal-based Santé Cannabis, Quebec’s first clinical research organization specializing in cannabis and cannabinoids for medical purposes. Dr. Antonio Vigano, and his colleagues at Santé Cannabis, designed this study to obtain clinical data on the safety and potential efficacy of various cannabis oils used in the practice of medicine under the Cannabis regulations.